Jayaram · Current medicinal chemistry 2011 · narrative review · n=?

NMNAT expression and its relation to NAD metabolism.

Cited 84 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Narrative review of biochemical mechanisms without systematic review or original human clinical data

PubMed 21517776 · doi:10.2174/092986711795590138 · record verified 2026-08-26

What was done

This paper is a narrative review summarizing the biochemical role of nicotinamide mononucleotide adenylyltransferase (NMNAT), its distinct isoforms and subcellular localizations, and its involvement in NAD metabolism, prodrug activation, and disease pathways.

What was found

The abstract reports no quantitative experimental data or summary statistics. It describes structural and localized features of three NMNAT isoforms: nuclear NMNAT-1 (homohexamer, chromosome 1p32-35), cytoplasmic NMNAT-2 (homodimer, chromosome 1q25), and mitochondrial NMNAT-3 (homotetramer). It reports that NMNAT catalyzes the conversion of antitumor prodrugs (tiazofurin and benzamide riboside) to active NAD analogs, acts as a chaperone protecting against neurodegeneration and axonal injury, correlates with DNA synthesis during the cell cycle, and displays relatively low activity in tumor cells.

Why it matters

Understanding the compartmentalized functions of NMNAT isoforms clarifies how NAD biosynthesis regulates cellular stress responses and identifies therapeutic targets for neurodegenerative disorders, multiple sclerosis, and cancer chemotherapy.

Limits

The abstract provides only descriptive biochemical mechanisms without systematic search methodology, sample size details, quantitative outcome metrics, or direct human clinical validation.

Cited by